← Russell 3000 cross-section

DVA DAVITA INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-04, not restated
Healthcare

Scale

Market cap
$11.4bn
Revenue TTM
$14.0bn
Net income TTM
$848m
Free cash flow
$1.6bn
Composite score
77.4
Sector rank
#658

Valuation

P / E
13.4
EV / EBITDA
3.8
EV / sales
0.8
FCF yield
14.13%
Earnings yield vs 10-yr
2.71pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
6.0%
EBITDA margin
20.2%
ROE
-110.8%
ROIC
Revenue growth
6.5%

Insider activity, last 90 days

Net open-market
$-54.26m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Total treatment volumes in the second quarter were slightly ahead of expectations due to, among other things, better than expected patient census that was primarily driven by lower than expected mortality partially offset by lower than expected incoming patient transfers and higher than expected missed treatments. These global economic conditions and political and regulatory developments also continue to exert pressure on our staffing and labor costs, which have increased year over year due to, among other factors, the continuation of inflationary conditions. The increase in our U.S. …DAVITA INC., 10-Q, period ended 2026-06-30, filed 2026-08-04

Read the full passage →